Actively Recruiting
Impact of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer
Led by Heinrich-Heine University, Duesseldorf · Updated on 2025-02-11
200
Participants Needed
1
Research Sites
263 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The introduction of PSMA diagnostics and therapy has fundamentally changed the treatment management of prostate cancer and has significantly replaced other clinical and radiological diagnostic methods. As a result, 18F-PSMA-1007 (Radelumin®) was approved in Germany and several EU countries, most recently in Germany in 01/2024, for use in primary staging of high-risk prostate cancer and re-staging in the context of biochemical recurrence (BCR). This could be seen as a milestone in the management of prostate cancer and will significantly promote the widespread use of PSMA-PET diagnostics in the coming years. The investigators now intend to prospectively generate evidence-based data in everyday clinical practice with this so-called Real-World-Evidence (RWE) study. The planned study will enable us to analyze the diagnostic accuracy of Radelumin® in more detail under everyday conditions, whereby dedicated examinations of certain subgroups and the prospective generation of a complete, high-quality database for the future use of artificial intelligence (AI) will be made possible.
CONDITIONS
Official Title
Impact of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male patients older than 18 years
- Planned 18F-PSMA-1007 PET/CT scan for initial diagnosis of prostate cancer
- Ability to provide informed consent
You will not qualify if you...
- PET/CT scans with limited quality due to technical errors or imaging artifacts
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Heinrich Heine University, Medical Faculty, University Hospital Düsseldorf
Düsseldorf, North Rhine-Westphalia, Germany, 40225
Actively Recruiting
Research Team
E
Emil Novruzov, Medical Doctor
CONTACT
E
Eduards Mamlins, Medical Doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here